Metallo-b-lactamase (MBL)-producing Pseudomonas aeruginosa are increasing in incidence in the UK, largely due to the emergence of several internationally recognized 'high-risk' clones (Wright et al., 2015) . These predominantly produce VIM carbapenemases, but isolates with IMP and NDM MBLs have also been identified, as have occasional isolates with other, rarer, MBLs such as DIM-1 [Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, unpublished data].
An isolate of P. aeruginosa, cultured in 2013 from the throat of an inpatient, was submitted for investigation of carbapenem resistance to Public Health England's AMRHAI Reference Unit. Local laboratory testing detected an MBL using a Rosco Diagnostica KPC/MBL Confirm kit (BioConnections). MICs were determined against the AMRHAI Reference Unit's standard Gram-negative antibiotic panel, which includes imipenem (±EDTA for MBL detection) and meropenem, using agar dilution and interpreted using British Society for Antimicrobial Chemotherapy criteria. Carbapenemase genes were sought by commercial microarray (Check-MDR CT102; Check-Points) and in-house PCR (Ellington et al., 2007) . Whole genome sequencing was performed using a HiSeq sequencing system (Illumina). Data were analysed using an in-house bioinformatics pipeline to infer multilocus sequence typing (MLST) profile and resistance genes were identified by mapping reads against a library curated in-house from publicly accessible databases (Doumith et al., 2015) . ).
The isolate was negative for acquired carbapenemase genes following screening by microarray, but bla SPM-1 was detected by in-house PCR and confirmed by Sanger sequencing. According to the referral form submitted with the isolate, the patient had no history of recent foreign travel. However, when further patient details were requested from the referring laboratory, it transpired that the patient had been hospitalized and undergone surgery during a visit to Brazil before subsequently being admitted upon return to the UK with a Hickman line in situ.
The isolate belonged to ST277, which has previously been shown to be an endemic clone in Brazilian hospitals and, like our isolate, is susceptible to colistin only (Fonseca et al., 2010; Silva et al., 2011) . Identification of SPM-1-producing P. aeruginosa from urban river water in Brazil may indicate that these organisms have spread beyond the hospital environment (Fontes et al., 2011) . SPM-1-positive P. aeruginosa was first reported in Europe following isolation in 2007 from a Swiss patient who had received medical treatment whilst in Brazil (Salabi et al., 2010) . MLST data for isolates belonging to ST277 have also been submitted to the P. aeruginosa MLST database (http://pubmlst.org/paeruginosa/) from Austria, Australia, Central Africa, China and Spain, although no information is provided as to whether these isolates harbour bla SPM-1 or whether they have connections with Brazil.
Short-read sequencing data mapped against the bla SPM -related genomic island (KP299160) with >98 % coverage and homology, indicating that bla SPM-1 was located within a Tn4371 integrative and conjugative element as described by Fonseca et al. (2015) . Association of bla SPM-1 with this mobile genetic element could potentially result in dissemination to other bacterial genera and species; bla SPM-1 has also been described in clinical isolates of Acinetobacter baumannii in Iran (Shahcheraghi et al., 2011) . Whole genome sequencing also identified the 16S rRNA methyltransferase gene rmtD1, which confers high-level resistance to all 4,6-disubstituted deoxystreptamine aminoglycosides and has been described associated with bla SPM-1 (Doi et al., 2007) . This is the first report of an SPM-1-producing isolate identified amongst more than 800 MBL-producing Pseudomonas spp. confirmed by the AMRHAI Reference Unit since screening began in 2001 (AMRHAI Reference Unit, unpublished data), and to our knowledge only the second report of the SPM-1-producing P. aeruginosa ST277 colistinonly-susceptible clone outside of Brazil. The opportunity for the global spread of SPM-1-producing P. aeruginosa following the 2016 Olympic Games in Rio de Janeiro has already been highlighted (Andrade et al., 2014) . Hospital laboratories should be alert to the possibility of SPM-1 in P. aeruginosa isolates resistant to all relevant carbapenems (i.e. imipenem, meropenem and doripenem), piperacillin/ tazobactam and usually ceftazidime in patients who have returned from Brazil. Laboratories that have implemented molecular testing for confirmation of carbapenemase production should note that the majority of commercial molecular carbapenemase detection assays focus on identification of the more prevalent bla VIM and bla NDM alleles (and some platforms offer limited coverage of bla IMP alleles); therefore, a high level of suspicion should be kept for isolates demonstrating good imipenem/EDTA synergy but negative in molecular assays, and such isolates should be referred to the national reference laboratory. 
